Prometheus Biosciences to Present at Jefferies Virtual Next Generation IBD Therapeutics Summit

Rhea-AI Summary

Prometheus Biosciences, Inc. (Nasdaq: RXDX) will participate in a fireside chat at the Jefferies Virtual Next Generation IBD Therapeutics Summit on October 19, 2021, at 11:30 a.m. ET. The session will feature Mark McKenna, CEO, and Allison Luo, M.D., CMO. Investors and interested parties can access a live and archived webcast through the company's website. Prometheus specializes in precision medicine for immune-mediated diseases, particularly inflammatory bowel disease (IBD), with its lead candidate PRA023 currently in Phase 2 trials for Ulcerative Colitis and Crohn's Disease.

SAN DIEGO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), today announced that Mark McKenna, Chairman and Chief Executive Officer and Allison Luo, M.D., Chief Medical Officer, will participate in a fireside chat at the Jefferies Virtual Next Generation IBD Therapeutics Summit on Tuesday, October 19, 2021 at 11:30 a.m. ET.

A live and archived webcast of the fireside chat will be available via the Events & Webcasts section of the Prometheus Biosciences website. A replay of the presentation will be available for 30 days following the event.

About Prometheus Biosciences

Prometheus Biosciences, Inc. is a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, starting first with inflammatory bowel disease (IBD). The Company’s precision medicine platform, Prometheus360, combines proprietary machine learning-based analytical approaches with one of the world’s largest gastrointestinal bioinformatics databases to identify novel therapeutic targets and develop therapeutic candidates to engage those targets.

The Company’s lead candidate, PRA023, is an IgG1 humanized monoclonal antibody (mAb) for the treatment of the two most common forms of IBD, Ulcerative Colitis (UC) and Crohn’s Disease (CD).  The Company has initiated enrollment in a Phase 2 trial in UC patients and a Phase 2a trial in CD patients, each utilizing a genetic-based companion diagnostic designed to identify patients more likely to respond to PRA023. 

Prometheus Biosciences Contact:
Noel Kurdi
VP Investor Relations and Communications
(646) 241-4400
nkurdi@prometheusbiosciences.com

Media Contact:
Jake Robison
CanaleComm, an Ashfield Health Company
(619) 849-5383
jake.robison@canalecomm.com

FAQ

When is the Jefferies Virtual Next Generation IBD Therapeutics Summit for RXDX?

The Jefferies Virtual Next Generation IBD Therapeutics Summit will take place on October 19, 2021, at 11:30 a.m. ET.

Who will represent RXDX in the fireside chat at the summit?

Mark McKenna, the CEO, and Allison Luo, M.D., the CMO of Prometheus Biosciences, will represent the company.

Where can I watch the RXDX fireside chat?

The fireside chat will be available via a live and archived webcast on the Prometheus Biosciences website.

What is the focus of Prometheus Biosciences?

Prometheus Biosciences focuses on precision medicine for immune-mediated diseases, starting with inflammatory bowel disease (IBD).

What is the lead candidate of RXDX?

The lead candidate of Prometheus Biosciences is PRA023, an IgG1 humanized monoclonal antibody for treating Ulcerative Colitis and Crohn’s Disease.

What clinical trials are currently underway for RXDX?

Prometheus Biosciences has initiated Phase 2 trials for PRA023 in Ulcerative Colitis and Crohn’s Disease patients.